News

Adapt has partnerd with biopharmaceutical firm Lightlake Therapeutics to develop treatments for opioid overdose. In December, Lightlake has agreed to license its opioid overdose reversal treatment to a

AR-12 is an orally-available small molecule. Data reported earlier shows that the mechanism of action of the molecule may include induction of host cell autophagy and inhibition of

The Enhanze platform is based on a proprietary recombinant human hyaluronidase enzyme (rHuPH20) that temporarily degrades hyaluronan, a chain of natural sugars in the body, to aid in

Both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have approved the brand name Galafold. Amicus Therapeutics chairman and CEO John Crowley said:

The VX-745 is an oral brain penetrant, which is highly selective and a potent inhibitor of the alpha isoform of the protein enzyme p38 mitogen activated protein kinase

Relistor is indicated for OIC treatment when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. The approval of Relistor is

Fluzone Quadrivalent, a commercially available vaccine, is the active comparator in the VAX2012Q clinical trial. Around 450 healthy adults, aged 18-64, will be enrolled for the trial. They

The original collaboration, initiated in 2013, was focused on applying gene therapy technology to genetically modify a patient’s own T cells to target and destroy cancer cells. BCMA

The required regulatory documents for the merger were approved by the New York State Attorney General on May 20, 2015. The combined entity, which will carry on the